## SciFinder

Page: 2

## **Bibliographic Information**

Preparation of 2-phenyi-4-quinolinecarboxylates as antitumor agents. Hesson, David P. (du Pont de Nemours, E. I., and Co., USA). U.S. (1987), 19 pp. Cont.-in-part of U.S. Ser. No. 605,104, abandoned. CODEN: USXXAM US 4680299 A 19870714 Patent written in English. Application: US 85-727808 19850426. Priority: US 83-516319 19830722; US 84-605104 19840430. CAN 109:54674 AN 1988:454674 CAPLUS (Copyright 2005 ACS on SciFinder (R))

## **Patent Family Information**

<u>Pa</u>	tent No.	<u>Kind</u>	<u>Date</u>	Application No.	<u>Date</u>
US	4680299	Α	19870714	US 1985-727808	19850426
AU	8430852	A1	19850124	AU 1984-30852	19840719
ΑŲ	583793	B2	19890511		
ZA	8405594	Α	19860326	ZA 1984-5594	19840719
CA	1288436	-A1	19910903	CA 1984-459263	19840719
Į DK	8403587	Α	19850123	DK 1984-3587	19840720
FI	8402928	Α	19850123	FI 1984-2928	19840720
FI	86987	В	19920731		
FI	86987	С	19921110	·	
NO	8402969	Α	19850123	NO 1984-2969	19840720
NO	167510	В	19910805	•	
NO	167510	C .	19911113		
JP	60042367	A2	19850306	JP 1984-149802	19840720
JP	05019549	B4	19930317		,
HU	35248	A2 .	19850628	HU 1984-2824	19840720
HU	194832	В	19880328		
ES	534509	A1	19850901	ES 1984-534509	19840720
SU	1393314	АЗ	19880430	SU 1984-3776940	19840720
IL	72471	A1	19881115°	IL 1984-72471	19840720
SU	1452480	A3	19890115	SU 1986-4000869	19860106
US	5032597	Α .	19910716	US 1987-30421	19870326
٠.			·		
Priority Application					
US	1983-516319	A2	19830722		
US	1984-605104	A2	19840430		
UŚ	1985-727808	АЗ -	19850426		

## **Abstract**

Title compds. I [R = (un)substituted cyclohexylphenyl, -phenoxyphenyl, -benzylphenyl, phenylthienyl, etc; R3 = H, C1-3 alkoxy; C1-2 alkyl; R4 = HO2C, its aminoalkyl ester; R5, R6, R7, R8 = H, Br, Cl, F, iodo, Me, F3C, MeS, Et;  $\geq$  2 of R5, R6, R7, R8 = H] and their salts, were prepd. Pfitzinger reaction of 5-fluoroisatin with 4-cyclohexylpropiophenone gave I (R = 4-cyclohexylphenyl; R3 = Me; R4, R5, R7, R8 = H; R6 = F) (II). II, at 25 mg/kg i.p., increased survival time of mice implanted with melanotic melanoma B16 25-27% over controls.